VX-745
- CAS No.
- 209410-46-8
- Chemical Name:
- VX-745
- Synonyms
- CS-1918;VD31745;VX-745, >=96%;VX-745(VX 745);VX-745 (Free base);NEFLAMAPIMOD;VX 745;Naluzotan Hydrochloride;Neflamapimod (VX745, VRT031745;Neflamapimod VX-745 MAPK inhibitor;Inhibitor,VX745,Neflamapimod,Autophagy,VX 745,inhibit,p38 MAPK
- CBNumber:
- CB8511364
- Molecular Formula:
- C19H9Cl2F2N3OS
- Molecular Weight:
- 436.26
- MDL Number:
- MFCD09834070
- MOL File:
- 209410-46-8.mol
- MSDS File:
- SDS
| Melting point | 261-264 °C |
|---|---|
| Boiling point | 578.9±60.0 °C(Predicted) |
| Density | 1.55±0.1 g/cm3(Predicted) |
| storage temp. | -20°C |
| solubility | ≥21.8 mg/mL in DMSO; insoluble in H2O; ≥2.1 mg/mL in EtOH with gentle warming and ultrasonic |
| form | powder |
| pka | -0.97±0.40(Predicted) |
| color | white to beige |
| FDA UNII | TYL52QM320 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H332-H335 |
| Precautionary statements | P261-P280-P305+P351+P338 |
| HS Code | 2933599590 |
VX-745 price More Price(37)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | SML1638 | VX-745 ≥98% (HPLC) | 209410-46-8 | 5MG | $108 | 2024-03-01 | Buy |
| Sigma-Aldrich | SML1638 | VX-745 ≥98% (HPLC) | 209410-46-8 | 25MG | $435 | 2024-03-01 | Buy |
| Cayman Chemical | 18075 | VX-745 ≥98% | 209410-46-8 | 1mg | $32 | 2024-03-01 | Buy |
| Cayman Chemical | 18075 | VX-745 ≥98% | 209410-46-8 | 5mg | $139 | 2024-03-01 | Buy |
| Cayman Chemical | 18075 | VX-745 ≥98% | 209410-46-8 | 10mg | $199 | 2024-03-01 | Buy |
VX-745 Chemical Properties,Uses,Production
Description
VX-745 is an inhibitor of p38α MAPK (IC50 = 9 nM). It is selective for p38α over p38β MAPK (Ki = 220 nM) as well as ERK, JNK, and a panel of 50 kinases when used at a concentration of 2 μM. VX-745 inhibits LPS-induced production of IL-1β and TNF-α in isolated human peripheral blood mononuclear cells (PBMCs; IC50s = 45 and 51 nM, respectively). It reduces disease severity in a type II collagen-induced mouse model of arthritis when administered at a dose of 10 mg/kg.
Chemical Properties
Pale Yellow Solid
Uses
VX 745 is a potent and selective inhibitor of p38α mitogen-activated protein (MAP) kinase. VX 745 is a potential anti-inflammatory agents. Studies suggest that VX 745 may be useful in the treatment of Werner syndrome.
Uses
VX 745 is a potent and selective inhibitor of p38α mitogen-activated protein (MAP) kinase. VX 745 is a potential anti-inflammatory agents. Studies suggest that VX 745 may be useful in the treatment of Werner syndrome.
Definition
ChEBI: A member of the class of pyrimidopyridazines that is 6H-pyrimido[1,6-b]pyridazin-6-one substituted at positions 2 and 5 by (2,4-difluorophenyl)sulfanyl and 2,6-dichlorophenyl groups respectively
Biochem/physiol Actions
VX-745 is a selective blood-brain barrier penetrant inhibitor of p38 MAPKα. VX-745 showed 20-fold selectivity for p38α over p38β and a Ki value of 220 nM. VX-745 has been shown to reduce inflammation in an arthritic (AIA) mouse model and to improve performance in aged rats.
storage
-20°C
References
[1]. bagley, m.c., et al., microwave-assisted ullmann c-s bond formation: synthesis of the p38alpha mapk clinical candidate vx-745. j org chem, 2009. 74(21): p. 8336-42.
[2]. dent, p., et al., mapk pathways in radiation responses. oncogene, 2003. 22(37): p. 5885-96.
[3]. dominguez, c., d.a. powers, and n. tamayo, p38 map kinase inhibitors: many are made, but few are chosen. curr opin drug discov devel, 2005. 8(4): p. 421-30.
[4]. duffy, j.p., et al., the discovery of vx-745: a novel and selective p38alpha kinase inhibitor. acs med chem lett, 2011. 2(10): p. 758-63.
[5]. bagley, m.c., et al., gram-scale synthesis of the p38alpha mapk-inhibitor vx-745 for preclinical studies into werner syndrome. future med chem, 2010. 2(9): p. 1417-27.
VX-745 Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Capot Chemical Co.,Ltd. | 571-85586718 +8613336195806 | sales@capotchem.com | China | 29797 | 60 |
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 32480 | 60 |
| Shandong chuangyingchemical Co., Ltd. | 18853181302 | sale@chuangyingchem.com | CHINA | 5909 | 58 |
| Alchem Pharmtech,Inc. | 8485655694 | sales@alchempharmtech.com | United States | 63711 | 58 |
| CONIER CHEM AND PHARMA LIMITED | +8618523575427 | sales@conier.com | China | 47465 | 58 |
| Xi'an Yutbon Pharmaceutical Technology Co., Ltd | 029-81140587 +8618717328141 | sales@yutbon.com | China | 437 | 58 |
| Unipharm pharmaceutical industry Co., Ltd | 536-8266195 +8613953676784 | lee@unipharm-sd.com | China | 1206 | 58 |
| Dayang Chem (Hangzhou) Co.,Ltd. | 571-88938639 +8617705817739 | info@dycnchem.com | CHINA | 52867 | 58 |
| Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 +1-2135480471 | sales@sarms4muscle.com | China | 10523 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6393 | 58 |